- My News
- All News
- Most Popular
Edwards Lifesciences announced Friday that the UK's Patents Court determined that one of Boston Scientific's patents related to transcatheter heart valve (THV) outer seals that was asserted against Edwards Lifesciences' Sapien 3 THV is invalid, while a second patent is valid and infringed. Edwards Lifesciences said it will seek to "appeal on specific aspects of the decision," adding the ruling does not affect commercial availability of the Sapien 3 valve.
According to Edwards Lifesciences, Boston Scientific has initiated litigation that "involves multiple patents in multiple venues, and will likely yield court actions over an extended period of time." The company added that it is not altering its financial guidance.
Edwards Lifesciences, which reported last month that THV therapy sales rose 29.2 percent to $432 million in the fourth quarter, recently brought proceedings to Ireland's Commercial Court against Boston Scientific and its Galway plant in a patent dispute over the latter's Lotus THV system and Lotus Edge valve system.
Did you like this article?